Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
151 participants
INTERVENTIONAL
2015-09-30
2021-02-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
End-to-end
Excision of the stricture and end-to-end anastomosis of the urethra.
End-to-end
Excision of the stricture and end-to-end anastomosis of the urethra.
Graft
Incision of the stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided.
Graft
Incision of stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
End-to-end
Excision of the stricture and end-to-end anastomosis of the urethra.
Graft
Incision of stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Patient is able and willing to sign informed consent
Patient is able and willing to complete all study requirements
Exclusion Criteria
Previous hypospadia surgery
Previous surgery for congenital curvature or Mb Peyronie
Previous pelvic irradiation therapy
Known grave psychiatric disorder
Haemophilia or other clotting disorders that cause bleeding diathesis
Use of medication to increase erectile function, such as PDE5-inhibitors and intracavernous injections, during the study
Any condition or situation, which, in the investigator's opinion, puts the patient at significant risk, could confound the study results, or may interfere significantly with the patient's participation in the study
18 Years
70 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sahlgrenska University Hospital
OTHER
Region Örebro County
OTHER
Helsinki University Central Hospital
OTHER
Oslo University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ole Jacob Nilsen
Consultant, Head of section
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexander Schultz, MD
Role: PRINCIPAL_INVESTIGATOR
Consultant
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Helsinki University Hospital
Helsinki, , Finland
Oslo University Hospital, Dept of Urology
Oslo, , Norway
Sahlgrenska University Hospital, Dept of Urology
Gothenburg, , Sweden
Örebro University Hospital, Dept of Urology
Örebro, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OUS-URO-SUPS
Identifier Type: -
Identifier Source: org_study_id